Overview

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors

Status:
NOT_YET_RECRUITING

Trial end date:
2027-01-01

Target enrollment:

Participant gender:

Summary

This is a Phase Ib study that will evaluate the Safety, Tolerability , Pharmacokinetics and Activity of HS-10370 in Combination With Other Anti-cancer Therapies in patients with KRAS G12C mutation advanced or metastatic solid tumors, especially in non-Small cell lung cancer (NSCLC) .

Phase:

PHASE1

Details

Lead Sponsor:

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Treatments:

Carboplatin
Cisplatin
Pemetrexed